Delving into the Latest Updates on Coherent Biopharma Hefei Co. Ltd. with Synapse

Overview

Basic Info

Introduction

Established in 2016, Coherent Biopharma is a clinical-stage biopharmaceutical company focused on R&D and commercialization of bi-targeting XDC drugs. The management team of the Company consists of many experts in biotechnology R&D, medicinal chemistry/CMC, clinical study, and business development, including several high-level experts in innovation and entrepreneurship awarded at National and Jiangsu Provincial levels.

Tags

Neoplasms

Small molecule-drug conjugates

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	1
Endocrinology and Metabolic Disease	1

Top 5 Drug Type	Count

Small molecule-drug conjugates	1

Top 5 Target	Count

FOLR1 x TRPV6 x Top I	1

1) Phase Ia: Evaluate the safety and tolerability of CBP-1019 for injection in patients with advanced lung cancer; determine the maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of CBP-1019 in patients with advanced lung cancer; 2) Phase Ib: Evaluate the objective response rate (ORR) of CBP-1019 for injection in patients with advanced lung cancer.

Start Date16 Oct 2023

Sponsor / Collaborator

Coherent Biopharma Hefei Co. Ltd.

CTR20231450

/ RecruitingPhase 1

评价注射用CBP-1019在晚期恶性实体瘤患者中安全性和耐受性、药代动力学及初步疗效的非随机、开放、首次用于人体的国际多中心Ⅰ/Ⅱ期临床研究

[Translation] A non-randomized, open-label, first-in-human, international, multicenter Phase I/II clinical study to evaluate the safety and tolerability, pharmacokinetics, and preliminary efficacy of CBP-1019 for injection in patients with advanced malignant solid tumors

1）Ⅰa期：评估CBP-1019在晚期恶性肿瘤患者中的安全性和耐受性；确定CBP-1019在晚期恶性肿瘤患者的最大耐受剂量（MTD）和Ⅱ期推荐剂量（RP2D）； 2）Ⅰb/Ⅱ期：评估CBP-1019在晚期恶性肿瘤患者中的客观缓解率（ORR）。

[Translation]

1) Phase Ia: Evaluate the safety and tolerability of CBP-1019 in patients with advanced malignant tumors; Determine the maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of CBP-1019 in patients with advanced malignant tumors; 2) Phase Ib/II: Evaluate the objective response rate (ORR) of CBP-1019 in patients with advanced malignant tumors.

Start Date14 Aug 2023

Sponsor / Collaborator

Coherent Biopharma Hefei Co. Ltd.

NCT05830097

/ Unknown statusPhase 1/2

An Open-Label, Non-randomized, Multinational, Multi-center Phase I/Ⅱ Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors

The primary objective of this phase I study is to evaluate the safety and potential efficacy and to determine the recommended phase 2 dose (RP2D) of CBP-1019, a bi-specific ligand conjugated drugs in patients with advanced solid tumors.

Start Date14 Mar 2023

Sponsor / Collaborator

Coherent Biopharma Hefei Co. Ltd.

100 Clinical Results associated with Coherent Biopharma Hefei Co. Ltd.

Login to view more data

0 Patents (Medical) associated with Coherent Biopharma Hefei Co. Ltd.

Login to view more data

100 Deals associated with Coherent Biopharma Hefei Co. Ltd.

Login to view more data

100 Translational Medicine associated with Coherent Biopharma Hefei Co. Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 07 Aug 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 1

1

Login to view more data